Harnessing the Natural Power of Birth Tissues
Surgenex® uses its patented Excellion® process to produce minimally manipulated products which conform to the FDA’s definition found in HCT/P Section 361. Following these standards allows Surgenex® to sell approved allograft products with confidence to healthcare providers.
Find out what sets us apart
Our products represent our commitment to pioneering the future today through innovation and expertise.Learn More
Continuously pushing forward, our team of scientists are redefining the industry through new techniques and processes.Learn More
Commitment to our providers and their patients is what truly sets us apart from competitors as we offer both resources and support.Learn More
Dedication, teamwork, and collaboration are the key components to our team's success both inside and outside the company.Learn More
Surgenex has assembled an executive team of experienced professionals with a proven track record of excellence and achievement. We strive to instill best in class quality, service, and value into every aspect of the organization to meet the precise needs of our customers.
Mr. Bullock has over a decade of experience in the medical industry working for PSS World Medical and McKesson Medical-Surgical. He founded Surgenex in 2014 with the first allograft product launch occurring in July 2015. His previous experience is with creating fast-growth companies with low overhead and operational excellence. He has led the rapid expansion of Surgenex and its product offerings. Mr. Bullock has an International Master's degree in Business from CW POST in New York, the European Business School in London, and the American University of Paris in Paris. Mr. Bullock's undergraduate degree is in Business Management from Missouri State University.
Mr. Robinson has nearly two decades of Private Equity and Venture Capital experience in CFO and Controller roles including previous experience working with tissue banks. Mr. Robinson has worked closely with many entrepreneurs through rapid growth cycles and M&A transaction. Mr. Robinson has a BS of Accounting and Business Management, and an MBA degree. He is also a Certified Valuation Analyst (CVA), and a Certified Merger and Acquisition Advisor (CM&AA).
Mr. Schallenberger brings over ten years of experience in the development, manufacture, and commercialization of innovative biologics. Mr. Schallenberger previously served as the Sr. Director of Marketing and Product Development at DCI Donor Services where he led a team to develop and commercialize a comprehensive line of orthobiologics and placental based allografts. Prior to DCI, Mr. Schallenberger held multiple roles of increasing responsibility including the Director of Scientific Affairs at Xtant Medical. Mr. Schallenberger holds a MS degree in Chemical Biology from The Scripps Research Institute and a BS in Biochemistry from the University of Montana.
Start the process of becoming a Surgenex® Provider